Tenet Healthcare Corp

Tenet Healthcare Corp(THC)股票分析

$267.250

-7.643 (-2.86%)收盤時

Loading chart…
最高
278.390
開盤
276.960
成交量加權均價
270.43
成交量
827.87K
市值
13.51B
最低
265.650
成交金額
223.88M
企業價值/稅息折舊攤銷前利潤(TTM)
6.54

Tenet Healthcare Corporation is a diversified healthcare services company. The Company's segments include Hospital Operations and Services (Hospital Operations) and Ambulatory Care. The Hospital Operations segment consists of its acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. The Company's subsidiaries operate approximately 50 hospitals serving primarily urban and suburban communities in eight states. The Hospital Operations segment also includes around 132 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency department and micro hospitals. It also provides revenue cycle management and value based care services. Ambulatory Care segment, through its USPI Holding Company, Inc. subsidiary, holds ownership interests in approximately 533 ambulatory surgery centers, and 26 surgical hospitals in 37 states. It also operates a Global Business Center in the Philippines.

AI 分析 of Tenet Healthcare Corp (THC)

買進

Tenet Healthcare Corp is a good buy right now due to its strong financial performance, with a gross margin of 78.70% and a year-to-date price increase of 33.99%. The stock is currently priced at $267.25, which is below the median analyst target of $284, suggesting potential for growth. However, the main risk is the forward P/E ratio of 12.53, which indicates that the stock may be overvalued if earnings do not meet expectations.

分析師評級(16)

-9.12% 下跌空間
持有
4 買進
12 持有
0 賣出
目前: 267.25
最低
229.00
平均
242.89
最高
260.00

BMO Capital

2026-09-22

目標價

$265

Market Perform

BofA

2026-08-10

目標價

$295

買進

Mizuho

2026-08-10

目標價

$290

優於大盤

Wells Fargo

2026-08-03

目標價

$281

增持

Goldman Sachs

2026-07-28

目標價

$305

買進

估值指標

Tenet Healthcare Corp(THC)目前預期本益比為 12.53,5 年平均預期本益比為 11.90。

預期本益比

合理
5 年均值 P/E
11.90
目前P/E
12.53
高估
13.93
低估
9.87

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.93
目前EV/EBITDA
6.54
高估
7.53
低估
6.32

預期股價營收比

高估
5 年均值 P/S
0.54
目前P/S
0.96
高估
0.75
低估
0.33

Alphio AI 對 THC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%THC

$152.71

情境價格

基

基準

基準 · 50%THC

$138.03

情境價格

悲

悲觀

悲觀 · 25%THC

$113.61

情境價格

持有 THC 的大戶

C

Crake Asset Management LLP

+ 持有THC

+5.63%

3個月報酬率

M

Meridiem Capital Partners LP

+ 持有THC

+3.28%

3個月報酬率

B

BW Gestao de Investimentos Ltda.

+ 持有THC

+2.45%

3個月報酬率

B

Boston Partners Global Investors, Inc.

+ 持有THC

+2.19%

3個月報酬率

P

Pale Fire Capital SE

+ 持有THC

-2.45%

3個月報酬率

M

Moore Capital Management, LP

+ 持有THC

-3.72%

3個月報酬率

THC 常見問題 —— 由 Alphio AI 解答

Tenet Healthcare Corporation is a diversified healthcare services company. The Company's segments include Hospital Operations and Services (Hospital Operations) and Ambulatory Care. The Hospital Operations segment consists of its acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. The Company's subsidiaries operate approximately 50 hospitals serving primarily urban and suburban communities in eight states. The Hospital Operations segment also includes around 132 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency department and micro hospitals. It also provides revenue cycle management and value based care services. Ambulatory Care segment, through its USPI Holding Company, Inc. subsidiary, holds ownership interests in approximately 533 ambulatory surgery centers, and 26 surgical hospitals in 37 states. It also operates a Global Business Center in the Philippines. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

Tenet Healthcare Corp is a good buy right now due to its strong financial performance, with a gross margin of 78.70% and a year-to-date price increase of 33.99%. The stock is currently priced at $267.25, which is below the median analyst target of $284, suggesting potential for growth. However, the main risk is the forward P/E ratio of 12.53, which indicates that the stock may be overvalued if earnings do not meet expectations.

16 analysts cover THC: 4 rate it Buy, 12 Hold and 0 Sell. The average price target is 242.89.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易